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Introduction
The cancers of the upper aerodigestive tract (UADT) are a group 
of malignancies comprising cancers of the oral cavity, pharynx 
and larynx (often referred to as head and neck cancers) and 
esophageal cancer. UADT cancer is the sixth most frequent can-
cer worldwide; it is estimated that head and neck squamous cell 
carcinoma (HNSCC) alone accounts for over 500,000 cases per 
year.1 UADT cancers show a striking geographical variation in 
worldwide incidence rates, and some parts of South America, such 
as Brazil and Argentina, are considered high-risk areas.1 However, 
the underlying etiology and reasons for this geographical varia-
tion are not fully understood. Despite considerable progress 
being made in early detection, diagnosis and treatment, advanced 
UADT cancer cases have poor prognosis with a high percentage of 
recurrences.2,3 This highlights the need for better understanding 
of the molecular mechanisms underlying UADT carcinogenesis 
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While genetic factors such as mutations and genetic poly-
morphisms in tumor suppressor genes have been implicated in 
UADT cancer etiology,4 epigenetic events have also been linked 
to UADT cancers. DNA methylation is considered an important 
epigenetic mechanism that underlies silencing of key regulatory 
genes in many human cancers, including UADT cancers.5-11 
Abnormal DNA hypermethylation within the promoters of vari-
ous cancer-associated genes is believed to be a common event in 
human malignancies.5,12,13 Recently, many studies have revealed 
the presence of somatically acquired DNA methylation changes 
in a large number of genes in UADT cancers, most notably head 
and neck squamous cell carcinoma (HNSCC).14-17 UADT can-
cers are causally linked to tobacco smoking and alcohol drinking, 
which are believed to act both independently and synergistically 
in the development and progression of cancer.18,19 In addition, in 
© 2012 Landes Bioscience.
Do not distribute.
www.landesbioscience.com Epigenetics 271
 REsEaRch papER REsEaRch papER
(81%) were between 41 and 70 y of age. The average age of 
patients of both genders was 57 y. The predominant UDAT 
tumors included in the study were from the oropharnyx 
(26%), larynx (24%) and oral cavity (20%). We catego-
rized the subjects as never-smokers (10%), those consuming 
0–20 pack-years (py) (23%), 20–40 py (31%), 40–60 py 
(21%) and over 60 py (14%). Alcohol consumption (grams of 
ethanol per day) groups were categorized into low (0–138 g/d, 
24%), medium (139–889 g/d, 25%) and high (>890 g/d, 
51%). For comparison, samples of exfoliated mouth epithelial 
cells samples from healthy subjects included in the analysis as 
controls were described previously in reference 23.
Methylation profiles of CDKN2A, MTHFR, TP53, GSTP1, 
MGMT, CHRNA3, MYOD1 and RASSF1A genes in UADT 
cancers. In our selection of relevant genes that are potential tar-
gets of aberrant DNA methylation in UADT tumors, we were 
guided by two criteria: (1) genes that may have an association 
with UADT carcinogenesis based on their supposed biological 
function, (2) genes that are newly identified as targets of methyl-
ation in cancer and (3) genes that are proposed to be the fre-
quent targets of hypermethylation in human cancers. Results of 
quantitative analysis of methylation status in UADT tumors and 
control samples (normal mouth exfoliated epithelial cells) are 
shown in Figures 1 and S2. Analysis of all the cases for meth-
ylation levels showed high levels of methylation in MYOD1, 
CHRNA3 and MTHFR in tumors. GSTP1, TP53, CDKN2A, 
MGMT and RASSF1A exhibited relatively low levels of methyla-
tion or were unmethylated. Comparison of mean methylation 
levels of all CpG sites in tumors and exfoliated mouth epithelial 
cells revealed a highly significant increase in methylation levels 
in tumors for CHRNA3 (p < 0.0001), MTHFR (p < 0.0001) 
and MYOD1 (p < 0.0001), as well as a moderate hypermethyl-
ation for CDKN2A (p < 0.05), whereas no significant difference 
in methylation levels for GSTP1, MGMT, RASSF1A and Tp53 
between tumor and control samples was observed (Fig. 1).
Analysis of DNA methylation frequency (defined as the per-
centage of tumor samples with methylation levels above 95% 
quantile levels in control exfoliated epithelial cells samples) 
showed that three genes (MYOD1, CHRNA3 and MTHFR) 
were most frequently methylated (82.7%, 69.6% and 64.7%, 
respectively), three genes (CDKN2A, RASSF1A and MGMT) 
exhibited intermediate methylation frequency (20.8%, 21.1% 
and 11.9%, respectively) and the remaining two genes (GSTP1 
and TP53) showed low levels of methylation frequency (9.7% 
and 7.0%, respectively) (Table 2).
Association between methylation levels and risk factor 
exposure. We first analyzed associations between the methyla-
tion of MTHFR, TP53, CDKN2A, GSTP1, MGMT, CHRNA3, 
MYOD1 and RASSF1A genes (both mean levels of all CpG sites 
or individual CpG sites) separately and with available epidemio-
logical and clinical information including sex, age, smoking sta-
tus and alcohol consumption. These factors were then included 
in a multivariate analysis. As shown in Table 3, UADT tumors 
from women exhibited higher methylation levels of CDKN2A 
(2.0% vs. 10.2%, p < 0.01), MTHFR (49.5% vs. 56.0%, 
p < 0.01) and MGMT (6.9% vs. 10.8%, p < 0.01) than those 
developing countries, HPV infection as well as dietary factors 
such as low folate intake and drinking of hot beverages may also 
be important risk factors.6,20-22 However, whether these risk fac-
tors promote the development and progression of UADT cancer 
through epigenetic mechanisms remains unknown.
In this study, we aimed to quantitatively identify changes in 
DNA methylation in UADT cancers and their potential associ-
ation with primary UADT cancer risk factors. To this end, we 
have taken advantage of a case-control study of UADT cancers 
involving seven centers in South America, using detailed lifestyle 
information and quantitative analysis of DNA methylation in a 
panel of cancer-associated genes. Our results identified aberrant 
DNA hypermethylation of specific genes in UADT cancer and its 
association with major risk factors.
Results
Patient characteristics. A total of 184 UADT cancer cases 
were included in the study (Table 1). Among the cases, 31% 
were women and 68% were men. A majority of the cases 
Table 1. patient’s information
UADT Tumors (n = 184)
Gender
Male 126
Female 58
Age
≤40 10
41–50 41
51–60 64
61–70 44
71+ 25
Topology
Oral cavity (tongue and floor of mouth) 38
Oropharynx 48
hypopharynx 21
Larynx 44
Esophagus 26
Other  7
Tobacco (pack years)
Never 20
0–20 42
20–40 58
40–60 38
60+ 26
Alcohol intake (g/d)
0–138 44
139–189 46
890–3119 46
3120+ 45
ND 3
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statistical significance. An increase in DNA methylation level of 
CDKN2A gene was observed in tumors from smokers, whereas 
hypermethylation of MYOD1 was observed in both smokers and 
non-smokers (Table 3).
We observed a significant inverse association between alco-
hol consumption and methylation of MGMT and CHRNA3, 
which exhibited lower levels of methylation in all strata. 
Hypermethylation of CDKN2A in tumors from alcohol drinkers 
was also observed; however this did not reach statistical signifi-
cance in any strata.
from men, whereas methylation levels of RASSF1A, TP53, 
GSTP1, CHRNA3, MYOD1 were not found to correlate with 
sex.
In addition, associations were observed between age and 
hypermethylation of CDKN2A, MYOD1, MGMT and CHRNA3 
(Table 3). MYOD1 exhibited a very high level of methylation in 
the older age groups (>40 y). Hypomethylation of GSTP1 was 
significantly associated with all age categories. We also observed 
increased risk associated with hypermethylation of MTHFR in 
the 45–59 y age group; however this association was of borderline 
Figure 1. The DNa methylation levels in UaDT tumors and control samples. (a) summary of the analysis of DNa methylation of individual cpG sites in 
eight genes in UaDT tumors and exfoliated epithelial cells (controls). (B) Graphical representation comparing DNa methylation levels in UaDT tumors 
and control samples. Box plots of the summary results obtained by the analysis of the mean levels of all cpG sites analyzed for a given gene and the 
statistical significance for differential methylation in tumors compared with exfoliated mouth epithelial cells (EEc) samples.
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frequently hypermethylated in UADT tumors are consistent with 
previous studies showing that MYOD1 is commonly inactivated 
in a broad spectrum of human cancers.28,29 In contrast, we found 
no marked changes in methylation levels of GSTP1 and Tp53 in 
UADT tumors, supporting the notion that unscheduled hyper-
methylation and presumably gene silencing associated with this 
epigenetic event, does not occur randomly, but rather in a gene-
specific manner.5,30
Our data showed that methylation levels of CDKN2A, 
MTHFR and MGMT in UADT tumors were correlated with 
sex, with females showing higher levels of methylation than 
males. There are few studies showing age- and sex-specific differ-
ences in DNA methylation level and patterns thereof.31,32 DNA 
methyl-ation analysis of a small panel of genes suggested that 
sex is a strong predictor of methylation levels. In contrast, high- 
resolution methylation profiling of three human chromosomes 
did not find any significant attributable effect of age and sex on 
methylation levels.33,34 However, a study of methylation levels 
in a panel of genes in subjects from a population-based cohort 
revealed sex differentials in DNA methylation levels of specific 
genes.32 Our findings are consistent with this notion and argue 
that gender may strongly influence DNA methylation levels in 
specific genes. Our results are also consistent with the notion that 
differences in DNA methylation states between the sexes may 
constitute the basis for gender-dependent susceptibility to expo-
sures to environmental epimutagens or endogenous toxic agents, 
and ultimately to differential susceptibility to diseases.35
Our results further revealed that CDKN2A, CHRNA3 and 
MYOD1 hypermethylation were significantly more frequent in 
older age groups (>40 y), whereas methylation levels of GSTP1 
was decreased. These results indicate that age can influence 
methylation of distinct loci in a gene-specific manner. Our data 
revealed higher levels of methylation in CDKN2A among alcohol 
drinkers, whereas methylation levels of CHRNA3 were signifi-
cantly lower in tumors of alcohol drinkers. There have been only 
few reports on associations between DNA methylation changes 
and alcohol consumption in human cancer, notably cancers of 
the head and neck, lung, liver and colorectum.31,36-38 Our find-
ings further strengthen the notion that alcohol consumption may 
interfere with the DNA methylation of specific genes, although 
the effect of alcohol on methylation levels may be dependent on 
gene locus-specific context.
Of note, we found a strong association between CDKN2A 
methylation levels and tobacco smoking status, whereas methyla-
tion levels of other genes studied were not significantly associated 
with smoking status. Methylation levels of CDKN2A were signifi-
cantly higher in all groups of smokers than among non-smokers. 
These results suggest that even a short period of smoking is suf-
ficient to induce aberrant methylation of CDKN2A, consistent 
with a previous study showing that smoking can influence aber-
rant methylation of specific genes in lung cancer.31 These findings 
further corroborate previous studies showing that hypermethyl-
ation of the CDKN2A promoter is significantly associated with 
tobacco exposure in head and neck squamous cell carcinoma11,39 
and lung cancer,40-42 although the precise underlying mecha-
nism remains to be elucidated. The observation that some genes 
Discussion
In the present study we quantitatively determined the methyl-
ation levels in the promoter regions of eight cancer-related genes 
in UADT tumors. Our results revealed DNA methylation 
changes specific for UADT cancers and identified risk factors 
associated with these changes. In UADT tumors, MYOD1 is the 
most frequently hypermethylated (82.7%) among the genes, fol-
lowed by CHRNA3 (69.6%). In addition, there was an increase 
in hypermethylation of all analyzed CpG sites of MYOD1, 
CHRNA3 and MTHFR in UADT tumors. These results are 
consistent with the notion that hypermethylation of tumor sup-
pressor genes and other cancer-associated genes may be selected 
for and fixed in tumor cells in accordance with the degree of 
growth advantage caused by their inactivation. Therefore, 
hypermethylation of MYOD1, CHRNA3 and MTHFR may 
confer a growth advantage to cancer cells and contribute to the 
cancer phenotype.
While other studies have reported hypermethylation of many 
cancer-associated genes, including CDKN2A and MYOD1,14-16,24 
our results reveal for the first time aberrant methylation and 
silencing of CHRNA3 in these cancer types. This suggests that 
hypermethylation of the CHRNA3 gene, a member of the family 
of genes encoding subunits of nicotinic acetylcholine receptors 
(nAChRs) clustered at lung cancer susceptibility locus 15q25,25 
that is frequently silenced in lung cancer,26 may also be involved 
in be epigenetic deregulation of nAChR receptors in UADT 
tumors. Similarly, our study identifies the frequent hypermethyl-
ation of MTHFR, the gene encoding the enzyme known to play 
a critical role in maintaining an adequate methionine pool,27 
in UADT tumors. Because the enzyme MTHFR catalyzes 
the synthesis of methionine and is required for its metabolite, 
S-adenosylmethionine (SAM), epigenetic deregulation of the 
enzyme may further alter DNA methylation states and contribute 
to the development of UADT cancers. Our observations that the 
MYOD1 gene, a key player involved in muscle differentiation, is 
Table 2. Frequency of hypermethylation in UaDT tumors compared 
with DNa methylation level in control exfoliated epithelial cells
Percentage of hyper-methylated 
samples*
Methylation  
cut-off value**
CDKN2A 20.78 2.57
CHRNA3 69.56 7.93
MTHFR 64.67 50.28
MYOD1 82.75 10.27
GSTP1 9.73 1.57
MGMT 11.89 20.05
RASSF1A 21.08 2.29
p53 7.02 2.3
*samples with methylation levels above the quantile representing the 
upper 95% of methylation in control exfoliated epithelial cells. **Meth-
ylation cut-off value was used for dichotomization and is defined as 
methylation level above which the sample is considered hypermethyl-
ated. For a given gene methylation cut-off value was set at 95% quantile 
levels in control samples.
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with some of the risk factors under study may be explained by 
the fact that hypermethylation (and consequent inactivation) of 
these genes may be a common but relatively late event in tumor 
development and may be independent of the initial stimuli that 
trigger oncogenic transformation. Alternatively, the factors 
(such as MYOD1) show low methylation levels in normal exfo-
liated cells and striking hypermethylation in UADT tumors 
may reflect the fact that epigenetic inactivation of these genes 
contributes to tumor development and thus is selected for dur-
ing oncogenic transformation. However, the lack of association 
Table 3. DNa methylation levels of genes analyzed in UaDT cancers, stratified by sex, age, topology, tobacco consumption and alcohol intake
CDKN2A MTHFR RASSF1A TP53 GSTP1 MGMT CHRNA3 MYOD1
*Mean  
(p value)
*Mean  
(p value)
*Mean  
(p value)
*Mean  
(p value)
*Mean  
(p value)
*Mean  
(p value)
*Mean  
(p value)
*Mean 
(p value)
Sex
Men 2.0 (<0.001) 49.51 (<0.001) 2.17 (0.402) 0.31 (0.107) 0.98 (0.669) 6.93 (<0.001) 15.54 (0.002) 24.90 (0.554)
Women 10.22- 56.01- 1.72- 0.62- 1.05- 10.79- 12.25- 25.98-
Age
<40 2.53- 47.70- 2.38- 1.24- 4.01- 5.58- 7.70- 4.84-
40–44 9.4 (0.001) 52.61 (0.138) 0.54 (0.475) 0.04 (0.047) 0.68 (<0.001) 7.19 (0.800) 13.72 (0.122) 29.91 (<0.001)
45–49 4.5 (0.613) 54.65 (0.018) 0.20 (0.338) 0.25 (0.171) 0.31 (<0.001) 8.59 (0.311) 15.07 (0.033) 24.22 (0.005)
50–54 4.7 (0.465) 54.15 (0.016) 2.40 (1.000) 0.79 (0.714) 0.77 (<0.001) 12.04 (0.001) 15.53 (0.010) 28.82 (<0.001)
55–59 1.8 (-0.06) 56.16 (0.001) 3.47 (0.814) 0.33 (0.178) 0.61 (<0.001) 9.67 (0.076) 16.38 (0.003) 29.59 (<0.001)
60–64 11.5 (<0.001) 52.63 (0.110) 5.37 (0.094) 0.39 (0.236) 0.51 (<0.001) 9.90 (0.063) 19.06 (<0.001) 30.87 (<0.001)
65–69 10.1 (<0.001) 52.68 (0.129) 0.32 (0.380) 0.36 (0.245) 0.56 (<0.001) 8.68 (0.285) 14.52 (0.066) 28.37 (0.001)
>70 4.5 (0.983) 51.52 (0.274) 0.92 (0.629) 0.42 (0.262) 0.65 (<0.001) 9.25 (0.137) 9.19 (0.967) 26.88 (0.001)
Alcohol consumption
0–138 1.96- 52.73- 3.03- 0.70- 0.97- 12.59- 23.18- 25.31-
139–889 6.6 (<0.001) 53.32 (0.970) 1.22 (0.037) 0.59 (0.978) 0.85 (0.959) 10.22 (0.042) 13.17 (<0.001) 25.42 (1.000)
890–3119 10.4 (<0.001) 49.23 (0.758) 1.83 (0.264) 0.46 (0.736) 1.23 (0.639) 9.63 (0.006) 9.68 (<0.001) 26.47 (0.919)
3120+ 2.9 (0.991) 55.30 (0.152) 4.53 (0.152) 0.93 (0.832) 1.09 (0.972) 9.80 (0.022) 9.56 (<0.001) 24.56 (0.978)
Tobacco pack years
Never 1.4- 50.60- 1.85- 0.33- 0.82- 8.94- 12.92- 20.49-
0–20 8.3 (<0.001) 53.09 (0.267) 1.36 (0.930) 0.39 (0.999) 1.31 (0.246) 8.97 (1.000) 16.16 (0.340) 30.47 (0.034)
20–40 9.9 (<0.001) 53.18 (0.178) 2.79 (0.542) 0.65 (0.589) 1.18 (0.430) 8.56 (0.986) 9.72 (0.310) 28.80 (0.068)
40–60 6.1 (<0.001) 54.13 (0.065) -0.66 (0.018) 0.19 (0.967) 0.76 (0.997) 10.07 (0.691) 16.87 (0.201) 25.40 (0.406)
60+ 4.9 (0.003) 52.81 (0.415) 4.40 (0.027) 0.78 (0.450) 1.01 (0.914) 7.77 (0.716) 13.82 (0.961) 22.04 (0.958)
Topography
Op 4.3- 52.91- 3.09- 0.45- 1.16- 11.76- 16.38- 29.62-
hp 5.6 (0.771) 57.30 (0.011) 3.19 (1.000) -0.11 (0.943) 1.56 (0.652) 7.95 (0.003) 11.56 (0.003) 26.52 (0.732)
Oc/Op/hp/
NOs
22.0 (<0.001) 47.60 (0.287) -2.69 (0.002) 0.57 (1.000) 0.75 (0.983) 8.78 (0.690) 7.77 (0.239) 19.28 (0.316)
Larynx 2.8 (0.584) 52.93 (1.000) 1.27 (0.054) 0.07 (0.612) 0.96 (0.966) 11.15 (0.994) 16.93 (0.998) 23.54 (0.060)
Oc/OF/hF/
larynx
-1.2 (0.212) 58.02 (0.506) -0.49 (0.293) -0.05 (0.987) 0.51 (0.897) 10.25 (0.996) ND ND
Other parts 
of Oc
3.8 (1.000) 55.80 (0.318) 1.11 (0.154) 0.32 (1.000) 1.02 (0.999) 5.53 (<0.001) 9.10 (<0.001) 34.10 (0.666)
Tongue 13.2 (<0.001) 48.09 (0.149) 2.08 (0.980) 1.34 (0.299) 0.99 (1.000) 11.34 (1.000) 25.29 (0.165) 31.57 (1.000)
Floor of 
mouth
8.8 (0.001) 48.62 (0.067) 1.78 (0.743) 1.12 (0.358) 1.13 (1.000) 8.74 (0.125) 12.16 (0.063) 19.29 (0.002)
Esophagus 6.1 (0.214) 53.68 (0.998) 2.28 (0.923) 0.29 (0.998) 0.80 (0.701) 5.97 (<0.001) ND 26.97 (0.981)
Oc, oral cavity; Op, oropharynx; hp, hypopharynx; *mean of methylation at all cpG sites analyzed at a given gene promoter.
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used for extraction of genomic DNA using Buccal AMP DNA 
extraction kit.
Bisulfite conversion and pyrosequencing analysis of DNA 
methylation. DNA methylation levels in the selected panel of 
genes were examined by pyrosequencing, which allows sensitive 
and quantitative analysis of DNA methylation at multiple CpG 
sites as described previously in reference 31. Briefly, genomic DNA 
(0.5–1 μg) from UADT tumor samples and exfoliated mouth 
epithelial cells were treated with the EZ DNA Methylation-Gold 
kit (Zymo Research), according to the manufacturer’s protocol. 
The modified DNA was stored at -20°C until use. In order to 
investigate the methylation level of the genes under study, tar-
geted sequences localized in bona fide CpG islands were selected 
for the design of pyrosequencing assays (Fig. S1). For each gene, 
sets of primers were designed on an in silico modified DNA 
sequence. DNA amplifications were performed on bisulfite-
treated DNA using specific PCR primers (Table S1). Modified 
DNA (20–25 ng) was amplified in a total volume of 50 μL and 
10 μL of the PCR product was analyzed on an agarose gel, 
whereas the remaining 40 μL was used in a pyrosequencing assay 
using sequencing primers (Table S1). Pyrosequencing reactions 
were set up using the PyroGold Reagent kit (Biotage) and a pyro-
sequencing apparatus (PSQTM 96MA, Biotage), according to the 
manufacturer’s instructions. The methylation levels at the target 
CpGs were evaluated by converting the resulting pyrograms to 
numerical values for peak heights and expressed either as percent-
age of methylation of individual CpG sites or as the mean of all 
CpG analyzed at a given gene promoter.31
Statistical analysis. All methylation data were generated with-
out knowledge of the exposure status of the subjects or the histo-
logical features of the samples analyzed. To compare methylation 
levels in UADT tumor samples and control samples, we used the 
Wilcoxon rank-sum test, which allows the comparison of two 
groups of independent but continuous samples. Multivariate lin-
ear regression analysis was performed to test whether any of the 
risk factors (smoking and alcohol status) or clinical characteristics 
(sex, age and topology) was associated with DNA methylation. 
Cumulative tobacco consumption was calculated by multiplying 
smoking duration (in years) by smoking intensity (in the equiva-
lent of cigarette packs) and expressed as pack-years. Alcohol con-
sumption (grams per day of ethanol) was categorized into four 
groups (0–138, 139–889, 890–3,119 and <3,120). Analyses were 
performed using SAS software, version 9.1 (SAS Institute). A p 
value of < 0.01 was considered statistically significant. To assess 
DNA hypermethylation frequency, we calculated the percentage 
of tumor samples with methylation levels of >95% quantile levels 
in exfoliated mouth epithelial cells samples (controls).
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sex-specific differences in methylation patterns and their associa-
tion with various risk factors such as age, smoking and alcohol 
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provide the basis for the development of epigenetics-based strate-
gies for the risk assessment of UADT cancer.
Materials and Methods
Cancer samples and controls. This study is based on an inter-
national multi-center case-control study of UADT cancers con-
ducted in seven centers in South America (São Paulo, Goiania, 
Rio de Janeiro, Pelotas and Porto Alegre in Brazil; Buenos Aires 
in Argentina; and La Havana in Cuba).43 Cases were patients 
with newly diagnosed UADT cancer with no prior treatment. 
The incident cancer cases and hospital controls were recruited 
and informed consent was obtained from all study subjects. 
Each subject answered a detailed lifestyle questionnaire, includ-
ing basic demographic characteristics and a detailed history of 
tobacco, alcohol and maté use, which was administered face-to-
face in the hospital by a trained interviewer.22,43 Ever-smokers 
were defined as having smoked on average one cigarette, one cigar 
or one pipefill a day for at least one year. Individuals who quit 
smoking more than a year before the interview were considered 
to be former smokers. Ever-alcohol drinkers were defined as hav-
ing ever consumed alcoholic drinks. Individuals who quit drink-
ing more than a year before the interview were considered to be 
former drinkers. Fresh tumor samples were collected from cases 
whenever possible. Among these, a subset of 184 tumors strati-
fied into several subgroups was selected for DNA methylation 
analysis (Table 1). The control samples consisting of 45 samples 
of exfoliated mouth epithelial cells from healthy individuals were 
also included in the analysis.23 Ethical approvals were obtained 
from the relevant local ethical committees, and this study was 
approved by the institutional review board of the International 
Agency for Research on Cancer (IARC).
DNA extraction. DNA was extracted from freshly fro-
zen tumors using a standard Qiagen DNA Tissue Kit protocol 
as described previously in reference 43. A total of 184 UADT 
tumors clustered in different groups according to associated risk 
factors were included in DNA methylation analysis (Table 1). 
In addition, 45 samples of mouth exfoliated epithelial cells were 
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